BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal AdenocarcinomaCRC (Colorectal Cancer)Metastatic Non-Small Lung Cell CancerMetastatic Colorectal Cancer (CRC)KRAS G12AKRAS G12CKRAS G12DKRAS G12S
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
- Target Recruit Count
- 287
- Registration Number
- NCT06917079
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath